{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:59:25Z","timestamp":1794639565865,"version":"4.9.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Amyloid plaques and tau tangles are pathological hallmarks of Alzheimer\u2019s disease (AD). Parkinson\u2019s disease (PD) results from the accumulation of \u03b1-synuclein. TAR DNA-binding protein (TDP-43) and total tau protein (T-Tau) play roles in FTD pathology. All of the pathological evidence was found in the biopsy. However, it is impossible to perform stein examinations in clinical practice. Assays of biomarkers in plasma would be convenient. It would be better to investigate the combinations of various biomarkers in AD, PD and FTD. Ninety-one subjects without neurodegenerative diseases, 76 patients with amnesic mild cognitive impairment (aMCI) or AD dementia, combined as AD family, were enrolled. One hundred and nine PD patients with normal cognition (PD-NC) or dementia (PDD), combined as PD family, were enrolled. Twenty-five FTD patients were enrolled for assays of plasma amyloid \u03b2 1\u201340 (A\u03b2\n                    <jats:sub>1\u201340<\/jats:sub>\n                    ), A\u03b2\n                    <jats:sub>1\u201342<\/jats:sub>\n                    , T-Tau, \u03b1-synuclein and TDP-43 using immunomagnetic reduction (IMR). The results show that A\u03b2s and T-Tau are major domains in AD family. \u03b1-synuclein is highly dominant in PD family. FTD is closely associated with TDP-43 and T-Tau. The dominant plasma biomarkers in AD family, PD family and FTD are consistent with pathology. This implies that plasma biomarkers are promising for precise and differential assessments of AD, PD and FTD in clinical practice.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-22647-6","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T06:05:36Z","timestamp":1666764336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Relevance of plasma biomarkers to pathologies in Alzheimer\u2019s disease, Parkinson\u2019s disease and frontotemporal dementia"],"prefix":"10.1038","volume":"12","author":[{"given":"Pai-Yi","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Che","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsien","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shieh-Yueh","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"22647_CR1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","volume":"13","author":"SE O'Bryant","year":"2017","unstructured":"O\u2019Bryant, S. E. et al. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 13, 45\u201358 (2017).","journal-title":"Alzheimers Dement."},{"key":"22647_CR2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"22647_CR3","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1212\/WNL.0000000000009724","volume":"95","author":"JL Ebenau","year":"2020","unstructured":"Ebenau, J. L. et al. ATN classification and clinical progression in subjective cognitive decline. Neurology 95, e46\u2013e58 (2020).","journal-title":"Neurology"},{"key":"22647_CR4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0197-4580(02)00076-3","volume":"23","author":"G Forloni","year":"2002","unstructured":"Forloni, G. et al. Protein misfolding in Alzheimer\u2019s and Parkinson\u2019s disease: Genetics and molecular mechanisms. Neurobiol. Aging 23, 957\u2013976 (2002).","journal-title":"Neurobiol. Aging"},{"key":"22647_CR5","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1089\/ars.2009.2490","volume":"11","author":"JM Tan","year":"2009","unstructured":"Tan, J. M., Wong, E. S. & Lim, K. L. Protein misfolding and aggregation in Parkinson\u2019s disease. Antioxid. Redox Signal 11, 2119\u20132134 (2009).","journal-title":"Antioxid. Redox Signal"},{"key":"22647_CR6","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","volume":"21","author":"C Soto","year":"2018","unstructured":"Soto, C. & Pritzkow, S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat. Neurosci. 21, 1332\u20131340 (2018).","journal-title":"Nat. Neurosci."},{"key":"22647_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0896-6273(02)00761-4","volume":"35","author":"PJ Muchowsk","year":"2002","unstructured":"Muchowsk, P. J. Protein misfolding, amyloid formation, and neurodegeneration: A critical role for molecular chaperones?. Neuron 35, 9\u201312 (2002).","journal-title":"Neuron"},{"key":"22647_CR8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0300985815623997","volume":"53","author":"SA Youssef","year":"2016","unstructured":"Youssef, S. A. et al. Pathology of the aging brain in domestic and laboratory animals, and animal models of human neurodegenerative diseases. Veter. Pathol. 53, 327\u2013348 (2016).","journal-title":"Veter. Pathol."},{"key":"22647_CR9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13041-016-0272-9","volume":"9","author":"SS Adav","year":"2016","unstructured":"Adav, S. S. & Sze, S. K. Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling. Mol. Brain 9, 92 (2016).","journal-title":"Mol. Brain"},{"key":"22647_CR10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00018-019-03349-1","volume":"77","author":"CA Brunello","year":"2020","unstructured":"Brunello, C. A., Merezhko, M., Uronen, R. L. & Huttunen, H. J. Mechanisms of secretion and spreading of pathological Tau protein. Cell Mol. Life Sci. 77, 1721\u20131744 (2020).","journal-title":"Cell Mol. Life Sci."},{"key":"22647_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033583519000155","volume":"53","author":"T Sinnige","year":"2020","unstructured":"Sinnige, T., Stroobants, K., Dobson, C. M. & Vendruscolo, M. Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer\u2019s and Parkinson\u2019s diseases. Q. Rev. Biophys. 53, 1\u201343 (2020).","journal-title":"Q. Rev. Biophys."},{"key":"22647_CR12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","volume":"1739","author":"K Iqbal","year":"2005","unstructured":"Iqbal, K. et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta Mol. Basis Dis. 1739, 198\u2013210 (2005).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"22647_CR13","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"22647_CR14","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1084\/jem.20160833","volume":"213","author":"JL Guo","year":"2016","unstructured":"Guo, J. L. et al. Unique pathological tau conformers from Alzheimer\u2019s brains transmit Tau pathology in nontransgenic mice. J. Exp. Med. 213, 2635\u20132654 (2016).","journal-title":"J. Exp. Med."},{"key":"22647_CR15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WRG Gibb","year":"1988","unstructured":"Gibb, W. R. G. & Lees, A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychol. 51, 745\u2013752 (1988).","journal-title":"J. Neurol. Neurosurg. Psychol."},{"key":"22647_CR16","first-page":"142","volume":"43","author":"IRA Mackenzie","year":"2001","unstructured":"Mackenzie, I. R. A. The pathology of Parkinson\u2019s disease. BCMJ 43, 142\u2013147 (2001).","journal-title":"BCMJ"},{"key":"22647_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41586-021-04199-3","volume":"601","author":"D Arseni","year":"2022","unstructured":"Arseni, D. et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 601, 139\u2013143 (2022).","journal-title":"Nature"},{"key":"22647_CR18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fnins.2019.00335","volume":"13","author":"BA Berning","year":"2019","unstructured":"Berning, B. A. & Walker, A. K. The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front. Neurosci. 13, 335 (2019).","journal-title":"Front. Neurosci."},{"key":"22647_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1590\/S1980-5764-2016DN1002003","volume":"10","author":"LP Schilling","year":"2016","unstructured":"Schilling, L. P. et al. Imaging Alzheimer\u2019s disease pathophysiology with PET. Dement. Neuropsychol. 10, 79\u201390 (2016).","journal-title":"Dement. Neuropsychol."},{"key":"22647_CR20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/practneurol-2019-002468","volume":"20","author":"MA Kolanko","year":"2020","unstructured":"Kolanko, M. A. et al. Amyloid PET imaging in clinical practice. Pract. Neurol. 20, 451\u2013462 (2020).","journal-title":"Pract. Neurol."},{"key":"22647_CR21","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/alz.12356","volume":"17","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. & Hansson, O. Towards clinical application of Tau PET tracers for diagnosing dementia due to Alzheimer\u2019s disease. Alzheimers Dement. 17, 1998\u20132008 (2021).","journal-title":"Alzheimers Dement."},{"key":"22647_CR22","volume":"13","author":"R Ni","year":"2022","unstructured":"Ni, R. & Nitsch, R. M. Recent developments in positron emission tomography tracers for proteinopathies imaging in dementia. Front. Aging Neurosci. 13, 751897 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"22647_CR23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1515\/CCLM.2011.082","volume":"49","author":"N Mattsson","year":"2011","unstructured":"Mattsson, N. CSF biomarkers in neurodegenerative diseases. Clin. Chem. Lab. Med. 49, 345\u2013352 (2011).","journal-title":"Clin. Chem. Lab. Med."},{"key":"22647_CR24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13760-017-0816-5","volume":"117","author":"E Niemantsverdriet","year":"2017","unstructured":"Niemantsverdriet, E., Valckx, S., Bjerke, M. & Engelborghs, S. Alzheimer\u2019s disease CSF biomarkers: Clinical indications and rational use. Acta Neurol. Belg. 117, 591\u2013602 (2017).","journal-title":"Acta Neurol. Belg."},{"key":"22647_CR25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/jnnp-2020-323520","volume":"92","author":"IJ Swift","year":"2021","unstructured":"Swift, I. J. et al. Fluid biomarkers in frontotemporal dementia: Past, present and future. Neurol. Neurosurg. Psychiatry 92, 204\u2013215 (2021).","journal-title":"Neurol. Neurosurg. Psychiatry"},{"key":"22647_CR26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/biom12020329","volume":"12","author":"EH Kwon","year":"2022","unstructured":"Kwon, E. H. et al. Update on CSF biomarkers in Parkinson\u2019s disease. Biomolecules 12, 329 (2022).","journal-title":"Biomolecules"},{"key":"22647_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12031-011-9665-5","volume":"47","author":"H Rosenmann","year":"2012","unstructured":"Rosenmann, H. CSF biomarkers for amyloid and Tau pathology in Alzheimer\u2019s disease. J. Mol. Neurosci. 47, 1\u201314 (2012).","journal-title":"J. Mol. Neurosci."},{"key":"22647_CR28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13195-018-0397-4","volume":"10","author":"L Dayon","year":"2018","unstructured":"Dayon, L. et al. Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimers Res. Ther. 10, 66 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"22647_CR29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","volume":"84","author":"S Hall","year":"2015","unstructured":"Hall, S. et al. CSF biomarkers and clinical progression of Parkinson disease. Neurology 84, 57\u201363 (2015).","journal-title":"Neurology"},{"key":"22647_CR30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3233\/JAD-2010-100207","volume":"21","author":"J Hertze","year":"2010","unstructured":"Hertze, J. et al. Evaluation of CSF biomarkers as predictors of Alzheimer\u2019s disease: A clinical follow-up study of 4.7 years. J. Alzheimers Dis. 21, 1119\u20131128 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"22647_CR31","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren, N. et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology 98, e1137\u2013e1150 (2022).","journal-title":"Neurology"},{"key":"22647_CR32","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1038\/srep06446","volume":"10","author":"S Mondello","year":"2014","unstructured":"Mondello, S. et al. CSF and plasma amyloid-\u03b2 temporal profiles and relationships with neurological status and mortality after severe traumatic brain injury. Sci. Rep. 10, 6446 (2014).","journal-title":"Sci. Rep."},{"key":"22647_CR33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JAD-2010-100456","volume":"21","author":"ES Oh","year":"2010","unstructured":"Oh, E. S. et al. Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-\u03b2 in plasma. J. Alzheimers Dis. 21, 769\u2013773 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"22647_CR34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40120-019-00165-4","volume":"8","author":"P Oeckl","year":"2019","unstructured":"Oeckl, P. & Otto, M. A review on MS-based blood biomarkers for Alzheimer\u2019s disease. Neurol. Ther. 8, 113\u2013127 (2019).","journal-title":"Neurol. Ther."},{"key":"22647_CR35","doi-asserted-by":"crossref","DOI":"10.1063\/1.2827359","volume":"103","author":"JJ Chieh","year":"2008","unstructured":"Chieh, J. J. et al. Hyper-high-sensitivity wash-free magnetoreduction assay on biomolecules using high-Tc superconducting quantum interference devices. J. Appl. Phys. 103, 014703 (2008).","journal-title":"J. Appl. Phys."},{"key":"22647_CR36","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1021\/cn400129p","volume":"4","author":"MJ Chiu","year":"2013","unstructured":"Chiu, M. J. et al. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer\u2019s disease. ACS Chem. Neurosci. 4, 1530\u20131536 (2013).","journal-title":"ACS Chem. Neurosci."},{"key":"22647_CR37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fnagi.2017.00226","volume":"9","author":"LF Lue","year":"2017","unstructured":"Lue, L. F. et al. Plasma levels of A\u03b242 and Tau identified probable Alzheimer\u2019s dementia: Findings in two cohorts. Front. Aging Neurosci. 9, 226 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"22647_CR38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura, A. et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554, 249\u2013254 (2018).","journal-title":"Nature"},{"key":"22647_CR39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","volume":"143","author":"DS Smirnov","year":"2022","unstructured":"Smirnov, D. S. et al. Plasma biomarkers for Alzheimer\u2019s disease in relation to neuropathology and cognitive change. Acta Neuropathol. 143, 487\u2013503 (2022).","journal-title":"Acta Neuropathol."},{"key":"22647_CR40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","volume":"88","author":"CH Lin","year":"2017","unstructured":"Lin, C. H. et al. Plasma \u03b1-synuclein predicts cognitive decline in Parkinson\u2019s disease. Neurol. Neurosurg. Psychiatry 88, 818\u2013824 (2017).","journal-title":"Neurol. Neurosurg. Psychiatry"},{"key":"22647_CR41","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3389\/fneur.2019.01388","volume":"10","author":"CW Chang","year":"2019","unstructured":"Chang, C. W., Yang, S. Y., Yang, C. C., Chang, C. W. & Wu, Y. R. Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson\u2019s disease. Front. Neurol. 10, 1388 (2019).","journal-title":"Front. Neurol."},{"key":"22647_CR42","first-page":"7","volume":"8","author":"SY Yang","year":"2020","unstructured":"Yang, S. Y. et al. Development of assaying plasma TDP-43 utilizing immunomagnetic reduction. J. Neurol. Disord. 8, 7 (2020).","journal-title":"J. Neurol. Disord."},{"key":"22647_CR43","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2174\/156720512804142967","volume":"9","author":"MJ Chiu","year":"2012","unstructured":"Chiu, M. J. et al. New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer\u2019s disease. Curr. Alzheimer Res. 9, 1142 (2012).","journal-title":"Curr. Alzheimer Res."},{"key":"22647_CR44","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3233\/JAD-170784","volume":"62","author":"CE Teunissen","year":"2018","unstructured":"Teunissen, C. E. et al. Plasma amyloid-\u03b2 (A\u03b242) correlates with cerebrospinal fluid A\u03b242 in Alzheimer\u2019s disease. J. Alzheimer Dis. 62, 1857 (2018).","journal-title":"J. Alzheimer Dis."},{"key":"22647_CR45","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/cn500101j","volume":"5","author":"KY Tzen","year":"2014","unstructured":"Tzen, K. Y. et al. Plasma A\u03b2 but not Tau is related to brain PiB retention in early Alzheimer\u2019s disease. ACS Chem. Neurosci. 5, 830\u2013836 (2014).","journal-title":"ACS Chem. Neurosci."},{"key":"22647_CR46","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/hbm.22390","volume":"35","author":"MJ Chiu","year":"2014","unstructured":"Chiu, M. J. et al. Plasma Tau as a window to the brain\u2014Negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer\u2019s disease. Hum. Brain Mapp. 35, 3132\u20133142 (2014).","journal-title":"Hum. Brain Mapp."},{"key":"22647_CR47","volume":"26","author":"MJ Chiu","year":"2020","unstructured":"Chiu, M. J. et al. Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer\u2019s disease\u2014A cross-validation study. Nanomed. Nanotechnol. Biol. Med. 26, 102182 (2020).","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"22647_CR48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fnagi.2020.00212","volume":"12","author":"F Jiao","year":"2020","unstructured":"Jiao, F. et al. The validation of multifactor model of plasma A\u03b242 and total-Tau in combination with MoCA for diagnosing probable Alzheimer disease. Front. Aging Neurosci. 12, 212 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"22647_CR49","doi-asserted-by":"publisher","DOI":"10.1159\/000510325","author":"WC Lin","year":"2020","unstructured":"Lin, W. C., Lu, C. H., Chiu, P. Y. & Yang, S. Y. Plasma total \u03b1-synuclein and neurofilament light chain: Clinical validation for discriminating Parkinson\u2019s disease from normal control. Dement. Geriatr. Cogn. Disord. https:\/\/doi.org\/10.1159\/000510325 (2020).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"22647_CR50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"22647_CR51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"22647_CR52","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456\u20132477 (2011).","journal-title":"Brain"},{"key":"22647_CR53","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fnagi.2019.00222","volume":"11","author":"LF Lue","year":"2019","unstructured":"Lue, L. F. et al. Age-dependent relationship between plasma A\u03b240 and A\u03b242 and total Tau levels in cognitively normal subjects. Front. Aging Neurosci. 11, 222 (2019).","journal-title":"Front. Aging Neurosci."},{"key":"22647_CR54","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3233\/ADR-210310","volume":"5","author":"CJ Hu","year":"2021","unstructured":"Hu, C. J. et al. Assessment of high risk for Alzheimer\u2019s disease using plasma biomarkers in subjects with normal cognition in Taiwan: A preliminary study. J. Alzheimer Dis. Rep. 5, 761 (2021).","journal-title":"J. Alzheimer Dis. Rep."},{"key":"22647_CR55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-2003-40733","volume":"46","author":"A Holm","year":"2003","unstructured":"Holm, A., Savolainen, S. & Alafuzoff, I. Brain biopsy prior to treatment of Alzheimer\u2019s disease. Minim. Invasive Neurosurg. 46, 161\u2013164 (2003).","journal-title":"Minim. Invasive Neurosurg."},{"key":"22647_CR56","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate, A. et al. Segregation of a Missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature 349, 704\u2013706 (1991).","journal-title":"Nature"},{"key":"22647_CR57","doi-asserted-by":"crossref","first-page":"12393","DOI":"10.1021\/bi0612667","volume":"45","author":"S Schilling","year":"2006","unstructured":"Schilling, S. et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45, 12393\u201312399 (2006).","journal-title":"Biochemistry"},{"key":"22647_CR58","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1093\/hmg\/ddq160","volume":"19","author":"L Crews","year":"2010","unstructured":"Crews, L. & Masliah, E. Molecular mechanisms of neurodegeneration in Alzheimer\u2019s disease. Hum. Mol. Genet. 19, R12\u2013R20 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"22647_CR59","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.83.11.4040","volume":"83","author":"JG Wood","year":"1986","unstructured":"Wood, J. G., Mirrat, S. S., Pollock, N. J. & Binder, L. I. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein Tau (\u03c4). Proc. Natl. Acad. Sci. 83, 4040\u20134043 (1986).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"22647_CR60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/37.2.2492045","volume":"37","author":"JQ Trojanowski","year":"1989","unstructured":"Trojanowski, J. Q., Schuck, T., Schmidt, M. L. & Lee, V. M. Distribution of Tau proteins in the normal human central and peripheral nervous system. J. Histochem. Cytochem. 37, 209\u2013215 (1989).","journal-title":"J. Histochem. Cytochem."},{"key":"22647_CR61","doi-asserted-by":"crossref","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","volume":"94","author":"JD Doecke","year":"2020","unstructured":"Doecke, J. D. et al. Total A\u03b242\/A\u03b240 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology 94, e1580\u2013e1591 (2020).","journal-title":"Neurology"},{"key":"22647_CR62","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s43440-020-00107-0","volume":"72","author":"P Lewczuk","year":"2020","unstructured":"Lewczuk, P., \u0141ukaszewicz-Zaj\u0105c, M., Mroczko, P. & Kornhuber, J. Clinical significance of fluid biomarkers in Alzheimer\u2019s disease. Pharmacol. Rep. 72, 528\u2013542 (2020).","journal-title":"Pharmacol. Rep."},{"key":"22647_CR63","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13024-021-00503-x","volume":"16","author":"A Meneses","year":"2021","unstructured":"Meneses, A. et al. TDP-43 pathology in Alzheimer\u2019s disease. Mol. Neurodeg. 16, 84 (2021).","journal-title":"Mol. Neurodeg."},{"key":"22647_CR64","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s12035-015-9264-5","volume":"53","author":"XL Chang","year":"2016","unstructured":"Chang, X. L., Tan, M. S., Tan, L. & Yu, J. T. The role of TDP-43 in Alzheimer\u2019s disease. Mol. Neurobiol. 53, 3349\u20133359 (2016).","journal-title":"Mol. Neurobiol."},{"key":"22647_CR65","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s12276-020-00513-7","volume":"52","author":"M Jo","year":"2020","unstructured":"Jo, M. et al. The role of TDP-43 propagation in neurodegenerative diseases: Integrating insights from clinical and experimental studies. Exp. Mol. Med. 52, 1652\u20131662 (2020).","journal-title":"Exp. Mol. Med."},{"key":"22647_CR66","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1038\/s41467-020-19786-7","volume":"11","author":"YH Shih","year":"2020","unstructured":"Shih, Y. H. et al. TDP-43 interacts with amyloid-\u03b2, inhibits fibrillization, and worsens pathology in a model of Alzheimer\u2019s disease. Nat. Commun. 11, 5950 (2020).","journal-title":"Nat. Commun."},{"key":"22647_CR67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.brainres.2011.02.052","volume":"1386","author":"AM Herman","year":"2011","unstructured":"Herman, A. M., Khandelwal, P. J., Stanczyk, B. B., Rebeck, G. W. & Moussa, C. E. \u03b2-amyloid triggers ALS-associated TDP-43 pathology in AD models. Brain Res. 1386, 191\u2013199 (2011).","journal-title":"Brain Res."},{"key":"22647_CR68","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"22647_CR69","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.1074\/jbc.274.12.7619","volume":"274","author":"BI Giasson","year":"1999","unstructured":"Giasson, B. I., Uryu, K., Trojanowski, J. Q. & Lee, V. M. Mutant and wild type human \u03b1-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619\u20137622 (1999).","journal-title":"J. Biol. Chem."},{"key":"22647_CR70","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jnc.14808","volume":"150","author":"P Alam","year":"2019","unstructured":"Alam, P., Bousset, L., Melki, R. & Otzen, D. E. \u03b1-Synuclein oligomers and fibrils: A spectrum of species, a spectrum of toxicities. J. Neurochem. 150, 522\u2013534 (2019).","journal-title":"J. Neurochem."},{"key":"22647_CR71","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/01.jnen.0000230520.47768.1a","volume":"65","author":"F Mori","year":"2006","unstructured":"Mori, F. et al. Relationship among Alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia Nigra. J. Neuropathol. Exp. Neurol. 65, 808\u2013815 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"22647_CR72","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","volume":"120","author":"WJ Schulz-Schaeffer","year":"2010","unstructured":"Schulz-Schaeffer, W. J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Acta Neuropathol. 120, 131\u2013143 (2010).","journal-title":"Acta Neuropathol."},{"key":"22647_CR73","first-page":"1945","volume":"17","author":"OM El-Agnaf","year":"2003","unstructured":"El-Agnaf, O. M. et al. Alpha-synuclein implicated in Parkinson\u2019s disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 1945\u20131947 (2003).","journal-title":"FASEB J."},{"key":"22647_CR74","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/srep05797","volume":"4","author":"JF Kellie","year":"2014","unstructured":"Kellie, J. F. et al. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson\u2019s disease brain tissue by intact protein mass spectrometry. Sci. Rep. 4, 5797 (2014).","journal-title":"Sci. Rep."},{"key":"22647_CR75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3233\/JPD-191766","volume":"10","author":"CH Chen","year":"2020","unstructured":"Chen, C. H., Lee, B. C. & Lin, C. H. Integrated plasma and neuroimaging biomarkers associated with motor and cognition severity in Parkinson\u2019s disease. J. Parkinsons Dis. 10, 77\u201388 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"22647_CR76","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/WCO.0b013e3283168d1d","volume":"21","author":"IR Mackenzie","year":"2008","unstructured":"Mackenzie, I. R. & Rademakers, R. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr. Opin. Neurol. 21, 693\u2013700 (2008).","journal-title":"Curr. Opin. Neurol."},{"key":"22647_CR77","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1093\/brain\/awv220","volume":"138","author":"RH Tan","year":"2015","unstructured":"Tan, R. H. et al. TDP-43 proteinopathies: Pathological identification of brain regions differentiating clinical phenotypes. Brain 138, 3110\u20133122 (2015).","journal-title":"Brain"},{"key":"22647_CR78","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1086\/420978","volume":"74","author":"E Buratti","year":"2004","unstructured":"Buratti, E., Brindisi, A., Pagani, F. & Baralle, F. E. Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: A functional link with disease penetrance. Am. J. Hum. Genet. 74, 1322\u20131325 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"22647_CR79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0888-7543(03)00214-3","volume":"83","author":"HY Wang","year":"2004","unstructured":"Wang, H. Y., Fan, W. I., Jayaramakrishnan, B. & Shen, C. K. J. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 83, 130\u2013139 (2004).","journal-title":"Genomics"},{"key":"22647_CR80","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2017.01.008","volume":"35","author":"NT Olney","year":"2017","unstructured":"Olney, N. T., Spina, S. & Miller, B. L. Frontotemporal dementia. Neurol. Clin. 35, 339\u2013374 (2017).","journal-title":"Neurol. Clin."},{"key":"22647_CR81","doi-asserted-by":"crossref","first-page":"23281","DOI":"10.1038\/srep23281","volume":"6","author":"F Kametani","year":"2016","unstructured":"Kametani, F. et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci. Rep. 6, 23281 (2016).","journal-title":"Sci. Rep."},{"key":"22647_CR82","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ana.21425","volume":"64","author":"M Hasegawa","year":"2008","unstructured":"Hasegawa, M. et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 64, 60\u201370 (2008).","journal-title":"Ann. Neurol."},{"key":"22647_CR83","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11910-001-0100-0","volume":"1","author":"Y Yoshiyama","year":"2001","unstructured":"Yoshiyama, Y., Lee, V. M. Y. & Trojanowski, J. Q. Frontotemporal dementia and tauopathy. Curr. Neurol. Neurosci. Rep. 1, 413\u2013421 (2001).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"22647_CR84","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/NEN.0000000000000180","volume":"74","author":"I Ferrer","year":"2015","unstructured":"Ferrer, I. et al. Familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy. J. Neuropathol. Exp. Neurol. 74, 370\u2013379 (2015).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"22647_CR85","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/01.wnl.0000187068.92184.63","volume":"65","author":"JS Goldman","year":"2005","unstructured":"Goldman, J. S. et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 65, 1817\u20131819 (2005).","journal-title":"Neurology"},{"key":"22647_CR86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/humu.20086","volume":"24","author":"R Rademakers","year":"2004","unstructured":"Rademakers, R., Cruts, M. & van Broeckhoven, C. The role of Tau (MAPT) in frontotemporal dementia and related tauopathies. Hum. Mutat. 24, 277\u2013295 (2004).","journal-title":"Hum. Mutat."},{"key":"22647_CR87","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1038\/s41598-017-09009-3","volume":"7","author":"SY Yang","year":"2017","unstructured":"Yang, S. Y. et al. Analytical performance of reagent for assaying Tau protein in human plasma and feasibility study screening neurodegenerative diseases. Sci. Rep. 7, 9304 (2017).","journal-title":"Sci. Rep."},{"key":"22647_CR88","doi-asserted-by":"crossref","first-page":"17963","DOI":"10.1073\/pnas.1906124116","volume":"116","author":"K Araki","year":"2019","unstructured":"Araki, K. et al. Parkinson\u2019s disease is a type of amyloidosis featuring accumulation of amyloid fibrils of \u03b1-synuclein. PNAS 116, 17963 (2019).","journal-title":"PNAS"},{"key":"22647_CR89","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnen\/nlw070","volume":"75","author":"DH Hepp","year":"2016","unstructured":"Hepp, D. H. et al. Distribution and load of amyloid-\u03b2 pathology in Parkinson disease and dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 75, 936 (2016).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"22647_CR90","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fneur.2018.00809","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Tau pathology in Parkinson\u2019s disease. Front. Neurol. 9, 809 (2018).","journal-title":"Front. Neurol."},{"key":"22647_CR91","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/metabo10100380","volume":"10","author":"S Na","year":"2020","unstructured":"Na, S., Jeong, H., Park, J. S., Chung, Y. A. & Song, I. U. The impact of amyloid-beta positivity with 18F-Florbetaben PET on neuropsychological aspects in Parkinson\u2019s disease dementia. Metabolites 10, 380 (2020).","journal-title":"Metabolites"},{"key":"22647_CR92","doi-asserted-by":"crossref","first-page":"14820","DOI":"10.1038\/s41598-021-94345-8","volume":"11","author":"MS Baek","year":"2021","unstructured":"Baek, M. S., Lee, M. J., Kim, H. K. & Lyoo, C. H. Temporal trajectory of biofuid markers in Parkinson\u2019s disease. Sci. Rep. 11, 14820 (2021).","journal-title":"Sci. Rep."},{"key":"22647_CR93","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/jnnp.2007.127878","volume":"79","author":"P Edison","year":"2008","unstructured":"Edison, P. et al. Amyloid load in Parkinson\u2019s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 79, 1331 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22647-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22647-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22647-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T20:29:48Z","timestamp":1678393788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22647-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22647"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22647-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"8 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.Y. Yang is an employee and shareholder of MagQu Co., Ltd. The other authors do not have conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17919"}}